Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

HIV Infections 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Cachexia 1Acquired Immunodeficiency Syndrome 1

Interventions

Zidovudine 6tecogalan 4Vincristine 4Interferon alpha-2 4Doxorubicin 4Bleomycin 4sargramostim 3Specimen Handling 3Magnetic Resonance Spectroscopy 3interferon alfa-n1 2cabozantinib 2Nivolumab 2Cyclophosphamide 2Biopsy 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1pembrolizumab 1ibrutinib 1fludarabine 1efineptakin alfa 1axicabtagene ciloleucel 1Zalcitabine 1Vorinostat 1Tumor Necrosis Factor-alpha 1Transplantation Conditioning 1Taxes 1Sunitinib 1Polymerase Chain Reaction 1Pentoxifylline 1Paclitaxel 1O-(Chloroacetylcarbamoyl)fumagillol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × HIV Infections × Pentoxifylline × Clear all
NCT00000646 2021-11-02

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 1 Completed
54 enrolled

Acquired Immunodeficiency Syndrome, Cachexia, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡